Share Twitter LinkedIn Facebook Email Prof. Dan Aderka of the Sheba Medical Center discusses the Optimal Sequence of Targeted Agents for All RAS & BRAF Patient Sub-types; Latest Data Update and Clinical Experience. https://virtualgi2020.com/congress-program/ Advertisement
SGNTUC-024 Phase 1b/2 study: Tucatinib, trastuzumab, FOLFOX for HER2+ GI cancers Gastrointestinal 8 Mins Read